OPNT Opiant Pharmaceuticals

Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets close on Thursday August 6, 2020.  

The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday August 6, 2020. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13706176. To access the live webcast, please go to the investors section of Opiant’s website at . Following the live webcast, an archived version of the call will be available on the website.

Thursday August 6 @ 4:30 pm ET

Domestic: 877-407-0792
International:201-689-8263
Conference ID: 13706176
Webcast:   

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: .

Investor Relations Contacts:

Ben Atkins

VP of Corporate Communications and Investor Relations



(310) 589-5410

Dan Ferry

Managing Director

LifeSci Advisors, LLC



(617) 430-7576

EN
23/07/2020

Underlying

OPNTOpiant Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Opiant Pharmaceuticals

 PRESS RELEASE
Free
OPNT Opiant Pharmace...

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisiti...

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investm...

February 7, 2023 1 EN
 PRESS RELEASE
Free
OPNT Opiant Pharmace...

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiti...

Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a ke...

February 6, 2023 1 EN
 PRESS RELEASE
Free
OPNT Opiant Pharmace...

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of...

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose. The NDA was granted a Priority Review designation and has been given a Prescription Drug User Fee Act (PDU...

January 19, 2023 1 EN
 PRESS RELEASE
Free
OPNT Opiant Pharmace...

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission ...

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003, nasal nalmefene, for the treatment of opioid overdose. “We are very pleased to submit our NDA for OPNT003,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We believe the d...

November 22, 2022 1 EN
 PRESS RELEASE
Free
OPNT Opiant Pharmace...

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results

Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results SANTA MONICA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and nine months ended September 30, 2022. Recent highlights include: Finance Update Opiant and Emergent Biosolutions Inc. (EBS) settle legal dispute over royalties paid on NARCAN® Nasal Spray. The settlement includes a one-time payment, termination of the licens...

November 14, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch